Cargando…

Call for Comparative Effectiveness Research: Lowering A1c with Sitagliptin, Saxagliptin, or Cinnamon

Detalles Bibliográficos
Autores principales:	Fairman, Kathleen A., Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2009
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438167/ https://www.ncbi.nlm.nih.gov/pubmed/19803560 http://dx.doi.org/10.18553/jmcp.2009.15.8.696

Ejemplares similares

Rethinking the Whodunnit Approach to Assessing the Quality of Health Care Research -- A Call to Focus on the Evidence in Evidence-Based Practice
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Call for Letters Regarding Disclosure of Potential Conflicts of Interest in the Managed Care Literature -- Too Much, Too Little, or Just About Right?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
por: Vaidya, Varun, et al.
Publicado: (2016)

ADD or ADHD or What Exactly?--GIGO Part II and Other Lessons in Research with Administrative Claims
por: Curtiss, Frederic R., et al.
Publicado: (2007)

Making the World Safe for Evidence-Based Policy: Let's Slay the Biases in Research on Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Selling Real-World Health Care Research to Reluctant Buyers-Evidence-Based Education or Marketing a Defective Product?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Switching Antidepressant Drug Therapy Helps Some Patients Some of the Time--What TORDIA, STAR*D, and Observational Research Have Taught Us About Treatment-Resistant Depression
por: Curtiss, Frederic R., et al.
Publicado: (2008)

Still Looking for Health Outcomes in All the Wrong Places? Misinterpreted Observational Evidence, Medication Adherence Promotion, and Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Managed Care and Health Care Reform: Everything Old Is New Again
por: Fairman, Kathleen A., et al.
Publicado: (2009)

What Should Be Done About Bias and Misconduct in Clinical Trials?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Protecting Patients from Adverse Drug Events: Propoxyphene, PIMs, and Drugs to Avoid in Older Adults
por: Curtiss, Frederic R., et al.
Publicado: (2011)

Regulatory Actions on the Off-Label Use of Prescription Drugs: Ongoing Controversy and Contradiction in 2009 and 2010
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Tough Questions About the Value of Statin Therapy for Primary Prevention: Did JUPITER Miss the Moon?
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Clinical Quality Indicators and Provider Financial Incentives: Does Money Matter?
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

How Do Seniors Respond to 100% Cost-Sharing for Prescription Drugs? Quality of the Evidence Underlying Opinions About the Medicare Part D Coverage Gap
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Does Medicalization of Life Imperil Health? Expanding Indications for Diagnosis and Treatment of Chronic “Disease”
por: Fairman, Kathleen A., et al.
Publicado: (2011)

What Do We Really Know About VBID? Quality of the Evidence and Ethical Considerations for Health Plan Sponsors
por: Fairman, Kathleen A., et al.
Publicado: (2011)

VBID, the PPACA, and FREEE Medications: Did Politics Trump the Evidence About Cost Sharing?
por: Fairman, Kathleen A., et al.
Publicado: (2012)

Diabetes Drug Therapy -- First Do No Harm
por: Curtiss, Frederic R., et al.
Publicado: (2008)

The Elephant in the Pharmacy: Patient Choice Is the Big Challenge That No One Talks About in Affordability of Prescription Drugs
por: Fairman, Kathleen A., et al.
Publicado: (2007)

It Depends on What Mean Means: Averaging Versus Event Patterning in Analyses of Administrative Claims Data
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Lessons Learned from Randomized Trials and Recent Experience with Health Information Technology: Promising Interventions Meet Real-World Patient Care
por: Fairman, Kathleen A., et al.
Publicado: (2010)

It's Only a Pharmacoeconomic Model--Believe It or Not
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
por: Koyani, Chintan N., et al.
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

Nonadherence, Clinical Inertia, or Therapeutic Inertia?
por: Allen, J. Daniel, et al.
Publicado: (2009)

Prior Authorization and Clopidogrel Use - The Truth Lies in the Details
por: Jackson, Mark A., et al.
Publicado: (2009)

Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial
por: Zhou, Xiao-jun, et al.
Publicado: (2019)

The Editors Respond Regarding the Shortcomings in Reported Research on Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
por: Ramos, Mafalda, et al.
Publicado: (2019)

10 Tips for a Great Health Care Research Article
por: Fairman, Kathleen A.
Publicado: (2012)

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
por: Cho, Yong Kyun
Publicado: (2018)

HIPAA Effects on Health Research and PBM Functions in Drug Utilization Review
por: Curtiss, Frederic R.
Publicado: (2003)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
por: Li, Chun-Jun, et al.
Publicado: (2014)

Which Triptan? - Opportunity for Same or Better Outcomes at Lower Cost
por: Curtiss, Frederic R.
Publicado: (2004)

Methods to Attain Optimal Outcomes With Lipid-Lowering Drug Therapy
por: Curtiss, Frederic R.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_ceht2djk3pp4knaeh7t5g6u3ec